AMXI-5001 study for advanced cancers that won’t respond
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This Phase 1/2 trial tests AMXI-5001 in people with advanced cancers that have progressed or stopped responding to standard treatments. It’s mainly designed to find the safest dose and see early signs the treatment might work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed advanced or metastatic cancer that has progressed or not responded to treatments that usually help—or you cannot tolerate them.
- You must have at least one tumor that can be measured or followed with scans or certain lab tests.
- You are 18 years or older and can understand and sign the consent form.
- Your general health movement level is ECOG 0 to 1 (meaning you’re fairly active or fully ambulatory).
- You are not currently receiving cancer treatment at the time you join the study.
- You can’t have certain major heart problems or ECG (heart rhythm) issues, and you must not take medicines that strongly affect CYP3A4 (for example, some antibiotics/antifungals/anti-seizure meds, or grapefruit) around the study start.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called AGX101 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it can shrink tumors or slow their growth.
This trial tests an investigational drug called QXL138AM for people with advanced solid tumors or multiple myeloma that has not responded to standard treatments. The goal is to see if the drug is safe and effective.
This trial tests a new drug, MDX2001, for people with advanced solid tumors that have spread. The study aims to find the best dose and see how well it works.
This study tests a new immunotherapy drug called JANX014 in men with advanced prostate cancer that has stopped responding to hormone treatments. The trial aims to find the right dose and see if this drug can help slow or stop cancer growth.
This study tests an experimental drug called XYA02 for people with advanced solid tumors (like lung, ovarian, stomach, colorectal, or pancreatic cancer) that have come back or not responded to other treatments. The goal is to see if XYA02 can shrink tumors or slow their growth, and to find the best dose.
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Hear when a new Advanced Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.